Recent studies pointed out that conjugation of certain FDA-approved drugs, such as rivastigmine and donepezil, with chalcone scaffold led to generation of multifunctional MAO-B/ChE inhibitors, such as compound I with potent neuroprotective properties for AD [15]. Here, MAOB is linked to Alzheimer disease.